Abstract: Peptides comprising, in sequence, units selected from the amino acid residues 17 to 24 of VIP, and consisting at least of the amino acid residues 18 to 23, or an analogue thereof wherein one or more of the amino acid residues is replaced by an equivalent other amino acid; having anti-ulcer activity, a process for their preparation and their use as pharmaceuticals.

Abstract: A method for stimulating integumental melanocytes by the topical application of alpha-MSH analogs, and compositions comprising said analogs for use in the method are described.

Abstract: The present invention provides novel renin-inhibiting peptides of the formula X-A.sub.6 -B.sub.7 -C.sub.8 -D.sub.9 -E.sub.10 -F.sub.11 -G.sub.12 -H.sub.13 - I.sub.14 -Z, wherein the E.sub.10 -F.sub.11 moiety is a dihydroxyethylene isostere, X and Z are terminal groups, and the remaining variables are absent or are amino acid residues. Such inhibitors are useful for the control of hypertension.

Abstract: The invention concerns novel renin-inhibiting peptides which are modified as isosteres. These peptides are useful for treating renin-associated hypertension and hyperaldosteronism. Processes for preparing the peptides, compositions containing them and methods for using them are included. Also included is a diagnostic test using the peptides to determine the presence of renin-associated hypertension or hyperaldosteronism.

Abstract: Novel biologically active polypeptides, including a new class of transforming growth factor (TGF) polypeptides, which exhibit cell growth promoting properties are disclosed, as well as a process for isolating the TGF polypeptides from both human and murine cell lines in homogeneous form. Also disclosed are antigenic oligopeptides derived from the TGF polypeptides and antibodies raised therefrom which have application in the detection and treatment of malignancies and oligipeptides which have the ability to bind with cellular growth factor receptors and thus to interfere with transformation of certain cell lines into a cancerous state. Compositions and methods based on the disclosed peptides for detection and treatment of cancer and other proliferative diseases and for cell or tissue growth associated treatment, e.g., wound healing, ulcer therapy and bone loss are also described.

Abstract: Macromolecular monoclonal antibody compositions are provided which are capable of selectively forming stable bonds to cells having a predetermined concentration of at least one surface antigen, such concentration being greater in such cells than in other cells in the cell population, wherein the composition comprises a substrate and a plurality of monoclonal antibodies specific to said surface antigen or antigens, which antibodies are covalently bonded to the substrate.

Abstract: Antitumor effect of antitumor agents or treatments is favorably controlled by a growth factor. The growth factor enhances antitumor actions of antitumor agents or treatments including those against which tumor or cancer has acquired resistant, or reduces side effects due to the antitumor agents or treatments. The most typical growth factors include human epidermal growth factor. A lot of tumors or cancers including human ones has been tested and a lot of growth factors has been tested, and the favorable control has been determined.

Abstract: The invention relates to new peptides of the formula ##STR1## in which X, A, B, C, N', E, F, G and Z have the meanings indicated in the description, to a process for their preparation, to agents containing them, and to their use.

Abstract: A soluble form of the neutralizing antigen or rotavirus is provided. The antigen is formed by cloning DNA coding for VP7 protein into an expression vector and preparing deletion mutants coding for a soluble cell secreted neutralizing antigen. The preparation of the deletion mutants includes the removal of the DNA sequences coding for those amino acids of the VP7 protein responsible for its normal intracellular location and non-secretion characteristics. The deletion mutant may be used in the formation of stably transformed animal cell lines which contiuously secrete the antigen, or in the production of certain yeast strains which produce the soluble antigen with appropriate glycosylation.

Abstract: Certain polypeptide-phospholipid complexes consisting of the amphipathic, helical portion of human apo A and its analogs and a phospholipid are useful in the treatment of neonatal respiratory distress syndrome.

Abstract: A method for preparing polypeptides in bacteria with an alanine rather than a methionine at the N-terminus. The DNA sequence expressed has an alanine codon immediately following from one to about three contiguous methionine codons including a translation start signal and allows for the expression of polypeptides having the amino acid sequence of, for example, naturally occurring eucaryotic proteins such as various bovine and porcine somatotropin species.

Abstract: The present invention relates to novel synthetic antigens, conjugates and antibodies based upon specific peptide sequences and the production thereof. More particularly, the invention relates to a polypeptide which is a determinant site of a protein, the polypeptide having from 8 to 20 amino acid residues, having an amino-terminal amino acid and a carboxyl-terminal amino acid, wherein the polypeptide includes:(a) a four amino acid sequence which corresponds to the four amino acid sequence of a .beta.-turn of the protein;(b) a sequence of two to eight amino acid residues attached to the amino terminal (H.sub.2 N--) of the four amino acid sequence; and(c) a sequence of two to eight amino acid residues attached to the carboxyl terminal (--COOH) of the four amino acid sequence,wherein the amino acid residues of subparts (b) and (c) correspond to those attached to the amino terminal and the carboxyl terminal, respectively of the .beta.

Abstract: Polypeptides and derivatives thereof containing homocyclostatine and cyclostatine are useful for inhibiting the angiotensinogen-cleaving action of the enzyme renin.

Abstract: The invention relates to renin inhibiting compounds of the formula ##STR1## wherein A is hydrogen; loweralkyl; arylalkyl; OR.sub.10 or SR.sub.10 wherein R.sub.10 is hydrogen, loweralkyl or aminoalkyl; NR.sub.11 R.sub.12 wherein R.sub.11 and R.sub.12 are independently selected from hydrogen, loweralkyl, aminoalkyl, cyanoalkyl and hydroxyalkyl; ##STR2## wherein B is NH, alkylamino, S, O, CH.sub.2 or CHOH and R.sub.13 is loweralkyl, cycloalkyl, aryl, arylalkyl, alkoxy, alkenyloxy, hydroxyalkoxy, dihydroxyalkoxy, arylalkoxy, arylalkoxyalkyl, amino, alkylamino, dialkylamino, (hydroxyalkyl)(alkyl)amino, (dihydroxyalkyl)(alkyl)amino, aminoalkyl, alkoxycarbonylalkyl, carboxyalkyl, N-protected aminoalkyl, alkylaminoalkyl, (N-protected)(alkyl)aminoalkyl, dialkylaminoalkyl, (heterocyclic) alkyl or a substituted or unsubstituted heterocyclic; W is CO or CHOH and U is CH.sub.2 or NR.sub.2 with the proviso that when W is CHOH then U is CH.sub.2 ; R.sub.1 is loweralkyl, cycloaklylmethyl, benzyl, .alpha.,.alpha.

Abstract: A synthetic peptide, suitable for use in vaccination against or diagnosis of a disease caused by an enterovirus and especially by a poliovirus, is the peptide coded for by codons 286-290 in the RNA sequence coding for the structural capsid protein VP1 of poliovirus type 3 Sabin strain or by equivalent codons of another enterovirus or is an antigenic equivalent thereof, the numbers of the codons being counted from the 5'-terminus of the nucleotide sequence coding for the VP1 capsid protein.

Abstract: Endogenous and exogenous proteins, and fragments thereof, are chemically modified outside the body of an animal so that when injected into the animal they produce more antibodies against the unmodified protein than would injection of the unmodified protein or fragment alone. The chemical modification may be accomplished by attaching the proteins or fragments to carriers such as, for example, bacterial toxoids. The chemical modification can also be accomplished by polymerization of protein fragments. Proteins which can be modified include Follicle Stimulating Hormone and Human Chorionic Gonadotropin. The modified polypeptides may be administered to animals for the purpose of contraception, abortion or treatment of hormone-related disease states and disease disorders, treatment of hormone-associated carcinomas, and to boost the animals resistance to exogenous proteins, for example viral proteins.

Abstract: The invention relates to compounds of the formula ##STR1## in which R.sup.1 is absent or denotes hydrogen, alkyl or acyl, A denotes an acyl radical or an amino acid residue, B denotes an amino acid residue, and R.sup.2, R.sup.3 and R.sup.4 are as defined in the specification, and to their salts, to a process for their preparation, to pharmaceutical products containing them, and to their use as medicaments, and intermediates for the preparation of these compounds.

Abstract: Polypeptides containing fluorinated cyclostatine derivatives as antihypertensive agents.

Abstract: A novel polypeptide which is at least equivalent in biological activity to IFN-.gamma. and is resistant to dimerization and polymerization, a transformant which carries a DNA coding for a novel polypeptide, and a method of producing a novel polypeptide from the culture of the transformant.The DNA coding for the novel polypeptide can be produced, for example, starting with a known plasmid which contains the IFN-.gamma. gene (cDNA), namely pHITtrp1101 or pHITtrp 1201.Insertion of this DNA into a vector followed by introduction into a host gives the transformant. An antibody column is used for the purification of the polypeptide from the culture.The novel polypeptide produced can be used as an antiviral agent or an antitumor agent.

Abstract: Disclosed are an oncogene-related peptide characterized in that the peptide comprises a portion of the amino acid sequence of a gene product coded for by an oncogene, an antigen or immunogen formed from the oncogene-related peptide and a carrier, an antibody against such antigen or immunogen, and a method of determining a gene product coded for by an oncogene by an immunoreaction with use of such antibody.